residual neoplasm

Summary

Summary: Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)

Top Publications

  1. ncbi Modern diagnostics in acute leukemias
    Torsten Haferlach
    Laboratory for Leukemia Diagnostics, Medical Department III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistreet 15, 81377 Munich, Germany
    Crit Rev Oncol Hematol 56:223-34. 2005
  2. doi Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
    E Fronkova
    Department of Pediatric Hematology and Oncology, CLIP, Second Medical School, Charles University and University Hospital Motol, Prague, Czech Republic
    Leukemia 22:989-97. 2008
  3. ncbi Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936
    J J M van Dongen
    Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 17:2257-317. 2003
  4. doi Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease
    Yazhen Qin
    Laboratory of Cellular and Molecular Biology, Peking University Institute of Hematology, Peking University People s Hospital, 11 Xi Zhi Men South Street, Beijing 100044, People s Republic of China
    Leuk Res 33:384-90. 2009
  5. ncbi Predictors of reexcision findings and recurrence after breast conservation
    Melanie C Smitt
    Department of Radiation Oncology, Stanford University, Stanford, CA, USA
    Int J Radiat Oncol Biol Phys 57:979-85. 2003
  6. ncbi Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia
    M Matsushita
    Division of Cellular Signalling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Br J Haematol 112:916-26. 2001
  7. ncbi Circulating tumor cells in patients with breast cancer dormancy
    Songdong Meng
    Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8576, USA
    Clin Cancer Res 10:8152-62. 2004
  8. ncbi MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy
    P Belli
    Departments of Bio Imaging and Radiological Sciences, Institute of Hygiene Catholic University, Rome, Italy
    Clin Radiol 61:946-53. 2006
  9. ncbi Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy
    Savannah C Partridge
    Department of Radiology, University of California, San Francisco, Magnetic Resonance Science Center, 1 Irving St, Rm AC 109, San Francisco, CA 94143 1290, USA
    AJR Am J Roentgenol 179:1193-9. 2002
  10. ncbi Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
    V H J van der Velden
    Department of Immunology, Erasmus MC, Rotterdam, The Netherlands
    Leukemia 21:604-11. 2007

Research Grants

Detail Information

Publications319 found, 100 shown here

  1. ncbi Modern diagnostics in acute leukemias
    Torsten Haferlach
    Laboratory for Leukemia Diagnostics, Medical Department III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistreet 15, 81377 Munich, Germany
    Crit Rev Oncol Hematol 56:223-34. 2005
    ..The results serve as a mandatory prerequisite for individual treatment strategies and for the evaluation of treatment response using especially newly defined and highly specific MRD markers...
  2. doi Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
    E Fronkova
    Department of Pediatric Hematology and Oncology, CLIP, Second Medical School, Charles University and University Hospital Motol, Prague, Czech Republic
    Leukemia 22:989-97. 2008
    ..Our findings revealed that morphology-based ALL IC risk-group stratification allows the identification of most MRD high-risk patients, but fails to discriminate the MRD low-risk group assigned to therapy reduction...
  3. ncbi Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936
    J J M van Dongen
    Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 17:2257-317. 2003
    ..The BIOMED-2 multiplex tubes can now be used for diagnostic clonality studies as well as for the identification of PCR targets suitable for the detection of minimal residual disease...
  4. doi Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease
    Yazhen Qin
    Laboratory of Cellular and Molecular Biology, Peking University Institute of Hematology, Peking University People s Hospital, 11 Xi Zhi Men South Street, Beijing 100044, People s Republic of China
    Leuk Res 33:384-90. 2009
    ..Moreover, it might also avoid false negativity in the case of expression alteration...
  5. ncbi Predictors of reexcision findings and recurrence after breast conservation
    Melanie C Smitt
    Department of Radiation Oncology, Stanford University, Stanford, CA, USA
    Int J Radiat Oncol Biol Phys 57:979-85. 2003
    ..To identify predictors of reexcision findings and local recurrence in the setting of breast-conserving therapy with radiation...
  6. ncbi Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia
    M Matsushita
    Division of Cellular Signalling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Br J Haematol 112:916-26. 2001
    ....
  7. ncbi Circulating tumor cells in patients with breast cancer dormancy
    Songdong Meng
    Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8576, USA
    Clin Cancer Res 10:8152-62. 2004
    ....
  8. ncbi MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy
    P Belli
    Departments of Bio Imaging and Radiological Sciences, Institute of Hygiene Catholic University, Rome, Italy
    Clin Radiol 61:946-53. 2006
    ..To assess the accuracy of magnetic resonance imaging (MRI) in evaluating residual disease after neoadjuvant chemotherapy in patients with large breast cancers...
  9. ncbi Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy
    Savannah C Partridge
    Department of Radiology, University of California, San Francisco, Magnetic Resonance Science Center, 1 Irving St, Rm AC 109, San Francisco, CA 94143 1290, USA
    AJR Am J Roentgenol 179:1193-9. 2002
    ..Tumor sizes measured on the MR images and at the clinical examination were compared with the size of residual disease measured at pathology after surgery...
  10. ncbi Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
    V H J van der Velden
    Department of Immunology, Erasmus MC, Rotterdam, The Netherlands
    Leukemia 21:604-11. 2007
    ..Furthermore, the ESG-MRD-ALL guidelines will facilitate the comparison of MRD data obtained in different treatment protocols, including those with new drugs...
  11. doi Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia
    T Flohr
    Department of Pediatrics, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Leukemia 22:771-82. 2008
    ..In conclusion, MRD-PCR-based stratification using stringent criteria is feasible in almost 80% of patients in an international multicenter trial...
  12. ncbi Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    Br J Haematol 115:272-8. 2001
    ..Two-year actuarial PFS rate for negative patients was 91% compared with 0% for positive patients. We concluded that [(18)F]-FDG-PET has an important prognostic role in the post-treatment evaluation of HD patients...
  13. ncbi Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis
    Alison L Allan
    London Regional Cancer Program, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
    Breast Dis 26:87-98. 2006
    ....
  14. ncbi International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
    A C Rawstron
    HMDS, Leeds Teaching Hospitals, Leeds, UK
    Leukemia 21:956-64. 2007
    ..These techniques may be used as a tool for assessing response and comparing the efficacy of different therapeutic approaches...
  15. ncbi Useful markers for detecting minimal residual disease in cases of neuroblastoma
    Susumu Ootsuka
    Research Unit of Clinical Medicine, College of Pharmacy, Nihon University, Funabashi, Chiba, Japan
    Biol Pharm Bull 31:1071-4. 2008
    ..We concluded that TH is a better marker before the diagnosis of NB while PGP9.5 is a better marker to detect MRD after the diagnosis. Here, we describe our results on useful markers to detect MRD in patients with NB...
  16. pmc Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
    ....
  17. ncbi Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
    V H J van der Velden
    Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Dr Molewaterplein 50, Rotterdam 3015 GE, The Netherlands
    Leukemia 17:1013-34. 2003
    ..These networks also include standardization of technology as well as regular quality control rounds, both being essential for the introduction of RQ-PCR-based MRD detection in multicenter clinical treatment protocols...
  18. ncbi Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia
    Marco Montillo
    Department of Hematology, Laboratory of Flow Cytometry, Transfusion Medicine Service, Niguarda Ca Granda Hospital, Milano, Milan, Italy
    J Clin Oncol 24:2337-42. 2006
    ..Subsequent peripheral blood stem-cell (PBSC) collection and transplantation, tolerability, and pharmacokinetics also were assessed...
  19. pmc Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Mol Diagn 9:237-41. 2007
    ..We conclude that CCND1 has potential clinical utility as a novel molecular marker of MRD in the bone marrow of patients with metastatic NB...
  20. ncbi Mutated p53 as a molecular marker for the diagnosis of head and neck cancer
    Viola M M van Houten
    Department of Otolaryngology Head and Neck Surgery, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    J Pathol 198:476-86. 2002
    ..Molecular assessment of surgical margins using p53 mutations enables the selection of HNSCC patients at high risk for tumour recurrence, but tumour RNA seems at present to be a more specific biomolecule for analysis than tumour DNA...
  21. ncbi Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer
    E W Steyerberg
    Department of Medical Oncology, University Hospital Groningen, The Netherlands
    J Clin Oncol 16:269-74. 1998
    ..To validate predictions of the histology (necrosis, mature teratoma, or cancer) of residual retroperitoneal masses in patients treated with chemotherapy for metastatic nonseminomatous testicular germ cell tumor...
  22. ncbi Detection of minimal residual disease in a patient having acute myelogenous leukemia with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation
    Y Okoshi
    Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan
    Acta Haematol 105:45-8. 2001
    ....
  23. doi Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication
    Francesc Bosch
    Department of Haematology, Hospital Clinic de Barcelona, Barcelona, Spain
    Clin Cancer Res 14:155-61. 2008
    ..Fludarabine, cyclophosphamide, and mitoxantrone (FCM) results in a high response rate in previously treated patients with chronic lymphocytic leukemia (CLL). The aim of this study was to investigate FCM as frontline therapy in CLL...
  24. ncbi Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
    C M Wendtner
    Klinikum Grosshadern, Medical Clinic III, Ludwig Maximilians University, Munich, Germany
    Leukemia 18:1093-101. 2004
    ..7 months; P=0.036). In conclusion, a consolidation therapy with alemtuzumab is able to achieve molecular remissions and longer survival in CLL, but a safe treatment regimen needs to be determined...
  25. pmc Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients
    A Nissan
    Department of Surgery and Surgical Oncology Laboratory, Hadassah Hebrew University Medical Center, Mount Scopus, PO Box 24035, Jerusalem, Israel
    Br J Cancer 94:681-5. 2006
    ..This method may prove to be of value in breast cancer staging and prognosis evaluation...
  26. ncbi Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy
    Eric L Rosen
    Department of Radiology, Breast Imaging Division, Box 3808, Duke University Medical Center, Durham, NC 27710, USA
    AJR Am J Roentgenol 181:1275-82. 2003
    ..This study was undertaken to evaluate the ability of MRI to accurately show residual primary breast malignancy in women treated with neoadjuvant chemotherapy...
  27. ncbi Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    Paul Moreton
    Leeds Teaching Hospitals, NHS Trust, Great George St, Leeds, LS1 3EX United Kingdom
    J Clin Oncol 23:2971-9. 2005
    ..To test whether eradication of minimal residual disease (MRD) in B-cell chronic lymphocytic leukemia (CLL) by alemtuzumab is associated with a prolongation of treatment-free and overall survival...
  28. doi Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction
    R Ratei
    Department of Hematology and Oncology, Robert Roessle Clinic at HELIOS Klinikum Berlin, Charite Campus Buch, Germany
    Leukemia 23:528-34. 2009
    ..8%. These data show that the quantitative assessment of early response parameters, especially absolute BCs at day 15 in BM, has a predictive impact on the remission status after induction therapy...
  29. doi Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
    V H J van der Velden
    Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Leukemia 23:1073-9. 2009
    ..These data indicate that MRD diagnostics has added value for recognition of risk groups in infant ALL and that MRD diagnostics can be used for treatment intervention in infant ALL as well...
  30. ncbi Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study
    Viola M M van Houten
    Departments of Otolaryngology Head Neck Surgery, Pathology, and Clinical Epidemiology and Biostatistics, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 10:3614-20. 2004
    ..We have investigated whether TP53-mutated DNA in the surgical margins is suitable to identify patients with head and neck squamous cell carcinoma at risk for local and locoregional recurrence...
  31. pmc Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
    Jun J Yang
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    JAMA 301:393-403. 2009
    ..Pediatric acute lymphoblastic leukemia (ALL) is the prototype for a drug-responsive malignancy. Although cure rates exceed 80%, considerable unexplained interindividual variability exists in treatment response...
  32. ncbi Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases
    Roswitha Schumacher-Kuckelkorn
    Childrens Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Germany
    Pediatr Blood Cancer 45:195-201. 2005
    ..Neuroblastoma cells may lack GD2 expression at diagnosis and at recurrence. This observation has diagnostic and therapeutic implications...
  33. ncbi Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells
    Katrien Swerts
    Department of Pediatric Hematology and Oncology, Ghent University Hospital, Ghent, Belgium
    Clin Chem 52:438-45. 2006
    ..Standard cytomorphologic examination of BM aspirates is sensitive enough to detect single tumor cells. Consequently, more sensitive and specific detection methods are indispensable...
  34. ncbi American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
    Lisa A Carey
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Natl Cancer Inst 97:1137-42. 2005
    ....
  35. ncbi Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer
    F Denis
    Clinique d Oncologie Radiothérapie, Tours, France
    Eur J Surg Oncol 30:1069-76. 2004
    ..We prospectively compared the ability of magnetic resonance imaging (MRI) to measure residual breast cancer in patients treated with different neoadjuvant chemotherapy regimen...
  36. ncbi Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR
    Lars M Wagner
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Pediatr Hematol Oncol 28:635-41. 2006
    ..The selective expression of MYCN in tumor cells, and the sensitivity of detection of MYCN by RT-PCR noted in this and other studies, supports further evaluation of MYCN as a NB marker for molecular detection of minimal residual disease...
  37. ncbi A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer
    Roth Oakley
    Maxillofacial Surgery Oncology, King s College Hospital, Denmark Hill, London SE5 8RX, UK
    Clin Cancer Res 8:1984-94. 2002
    ..c. tumor models in nude mice, but it is anticipated that transduction of tumor cells in the muscle in immune-competent hosts may be more difficult...
  38. ncbi Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma
    Rie Ito
    Clinical Pharmacy, College of Pharmacy, Nihon University, Narashinodai, Funabashi, Chiba, Japan
    Biol Pharm Bull 27:315-8. 2004
    ..Therefore, we can use this method to detect tumor cell contamination before hematopoietic stem cell transplantation...
  39. ncbi Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1087-93. 2003
    ..Because therapy (myeloablation, immunotherapy, or differentiation) for MRD is applied at the time of clinical remission, objective surrogate markers are needed to gauge treatment efficacy...
  40. ncbi Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials
    V F Viprey
    Candlelighter s Children s Cancer Research Group, Leeds Institute of Molecular Medicine, Section of Experimental Oncology, St James s University Hospital, Leeds, UK
    J Pathol 216:245-52. 2008
    ..This same strategy could be exploited to select MD markers of other solid tumours from the large number of potential targets identified by microarray gene expression profiles...
  41. ncbi Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor
    U H Athale
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    J Pediatr Hematol Oncol 23:99-104. 2001
    ..However, the clinical significance of molecularly-detectable disease remains unknown. Further studies should aim to elucidate the therapeutic and prognostic implications of micrometastases detected by RT-PCR alone...
  42. ncbi Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study
    M Fukuda
    Department of Pediatrics, Nagoya University School of Medicine, Japan
    J Pediatr Hematol Oncol 23:10-3. 2001
    ..There was a statistically significant difference in disease-free survival between the two groups (P < 0.05). CONCLUSION: Persistence of MRD in BM may predict poor prognosis in advanced neuroblastoma...
  43. pmc Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow
    Katrien Swerts
    Department of Pediatric Hematology and Oncology, Ghent University Hospital, Belgium
    J Histochem Cytochem 53:1433-40. 2005
    ..This method is an indispensable tool for multicenter studies evaluating the clinical significance of minimal residual disease in neuroblastoma...
  44. ncbi Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma
    K Horibe
    Department of Pediatrics, Nagoya University School of Medicine, Japan
    Med Pediatr Oncol 36:203-4. 2001
    ..We have determined whether sequential molecular detection of minimal residual disease (MRD) in bone marrow (BM) could predict the outcome of patients with advanced neuroblastoma (NB)...
  45. pmc Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
    Anees B Chagpar
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Ann Surg 243:257-64. 2006
    ..To assess the accuracy of physical examination, ultrasonography, and mammography in predicting residual size of breast tumors following neoadjuvant chemotherapy...
  46. pmc Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma
    Irene Y Cheung
    Department of Pediatrics and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:7020-7. 2008
    ..Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD markers differentially expressed in tumors over normal marrow/blood...
  47. ncbi Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay
    Soledad Gallego
    Pediatric Oncology Unit, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Cancer Res Clin Oncol 132:356-62. 2006
    ..To assess if molecular detection of minimal disseminated disease by real-time reverse transcription and polymerase chain reaction (RT-PCR) could contribute to a better treatment stratification in patients with rhabdomyosarcoma (RMS)...
  48. ncbi Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring
    G Germano
    Laboratorio di Emato Oncologia, Dipartimento di Pediatria, Universita di Padova, Italy
    Leukemia 17:1573-82. 2003
    ....
  49. ncbi Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy
    Sven Becker
    Department of Gynecology and Obstetrics, University Hospital Tubingen, Tubingen, Germany
    Breast Cancer Res Treat 97:91-6. 2006
    ..020). Adjuvant treatment regimens are not able to completely eliminate cytokeratin-positive cells from the bone marrow. Prospective studies need to evaluate, whether these cells could become targets for additional adjuvant therapy...
  50. ncbi Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry
    J M Vose
    Lymphoma Working Committee of the Autologous Blood and Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 19:406-13. 2001
    ....
  51. ncbi Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia
    Daniel Steinbach
    University Children s Hospital Jena, Jena, Germany
    Clin Cancer Res 12:2434-41. 2006
    ..It is used for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is still a need for more suitable MRD markers...
  52. ncbi Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen?: a microsatellite analysis of specimen identity
    Dengfeng Cao
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Surg Pathol 29:467-73. 2005
    ..However, specimen switch can rarely occur, and if there is high grade or a lot of cancer on the biopsy with no or very minimal cancer in the radical prostatectomy specimen, one should evaluate for patient identity...
  53. ncbi Differential expression of 9-O-acetylated sialoglycoconjugates on leukemic blasts: a potential tool for long-term monitoring of children with acute lymphoblastic leukemia
    Santanu Pal
    Immunobiology Division, Indian Institute of Chemical Biology, Kolkata, India
    Int J Cancer 111:270-7. 2004
    ..We propose that close monitoring of 90 and 120 kDa 9-O-AcSGs may serve as a reliable index for long-term management of childhood ALL and merits therapeutic consideration...
  54. doi Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia
    Tim Luetkens
    Department of Oncology and Hematology, Center of Oncology, Hamburg, Germany
    Leuk Res 34:1647-55. 2010
    ..However, a broad picture of the expression of CT antigens and associated humoral immune responses in chronic myeloid leukemia (CML) is still missing...
  55. ncbi VX2 carcinoma in rabbits after radiofrequency ablation: comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor
    Tae Jung Kim
    Department of Radiology and Clinical Research Institute, Seoul National University Hospital and the Institute of Radiation Medicine, Seoul National University Medical Research Center, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Korea
    Radiology 234:423-30. 2005
    ....
  56. doi Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation
    Ulrike Bacher
    Clinic for Stem Cell Transplantation, University of Hamburg, Germany
    Exp Hematol 37:135-42. 2009
    ..Nucleophosmin (NPM1) mutations, with their high frequency in AML, were suggested to represent suitable MRD markers, but so far no study has evaluated their usefulness in the posttransplantation period...
  57. ncbi Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia
    Nicolas Tajeddine
    Laboratory of Cellular Physiology, Universite Catholique de Louvain, 1200 Brussels, Belgium
    Clin Chem Lab Med 44:548-55. 2006
    ..In these cases, the quantification of PRAME (preferentially expressed antigen of melanoma) transcripts could be useful...
  58. ncbi No residual cancer on radical prostatectomy after positive 10-core biopsy: incidence, biopsy findings, and DNA specimen identity analysis
    Kiril Trpkov
    Department of Pathology and Laboratory Medicine, Anatomical Pathology, Rockyview General Hospital, University of Calgary, Calgary, Alberta, Canada
    Arch Pathol Lab Med 130:811-6. 2006
    ..It is uncertain whether extensive prostate-specific antigen (PSA) testing and extended biopsies currently performed will increase the incidence of no residual cancer on subsequent prostatectomy...
  59. ncbi Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
    S Braun
    I Frauenklinik der Ludwig Maximilians Universität, Munich, Germany
    J Clin Oncol 18:80-6. 2000
    ..This study was designed to evaluate whether monitoring of micrometastases in bone marrow can predict the response to systemic chemotherapy in breast cancer...
  60. ncbi Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma
    J Kollermann
    Institute of Pathology, Hegau Clinic, Singen, Germany
    Eur Urol 38:714-20. 2000
    ..The present work was done to elucidate the initial characteristics of these tumors, to see if additional workup of these prostatectomy specimens is able to detect tumor vestiges and, if so, to describe their morphology...
  61. ncbi Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease
    V H J van der Velden
    Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 17:1834-44. 2003
    ....
  62. ncbi 'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases
    David G Bostwick
    Mayo Clinic, Rochester, Minnesota, USA
    BJU Int 94:57-8. 2004
    ..To determine the incidence and long-term follow-up of the 'vanishing cancer' phenomenon, as complete sampling of some radical prostatectomy (RP) specimens reveals no residual cancer...
  63. ncbi Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells
    Tomasz Szczepanski
    Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Blood 103:3798-804. 2004
    ....
  64. ncbi Pattern of immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Polish pediatric acute lymphoblastic leukemia patients--implications for RQ-PCR-based assessment of minimal residual disease
    Małgorzata Dawidowska
    Institute of Human Genetics, Polish Academy of Sciences, Department of Molecular and Clinical Genetics, Strzeszynska 32, 60 479 Poznan, Poland
    Leuk Res 30:1119-25. 2006
    ..These results are the first promising step for further development of MRD study in Polish patients according to current diagnostic standards...
  65. ncbi Determination of minimal residual disease in leukaemia patients
    Dario Campana
    Departments of Hematology Oncology and Pathology, St Jude Children s Research Hospital, University of Tennessee College of Medicine, Memphis, TN, USA
    Br J Haematol 121:823-38. 2003
  66. ncbi Ig and TCR gene rearrangements in childhood ALL is there ethnic and socio-economic diversity of rearrangement patterns?
    Carlos Alberto Scrideli
    Leuk Res 30:1065-6. 2006
  67. ncbi T cell receptor gamma (TCRG) gene rearrangements in Brazilian children with acute lymphoblastic leukemia: analysis and implications for the study of minimal residual disease
    Carlos A Scrideli
    Department of Pediatrics, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Av Bandeirantes, 3900, 14049 900 Ribeirao Preto, SP, Brazil
    Leuk Res 28:267-73. 2004
    ..This fact should be considered when standardizing consensus primers for the study of minimal residual disease in different populations...
  68. ncbi The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas
    Björn L D M Brücher
    Department of Surgery, Technical University of Munich, Munich, Germany
    Cancer 106:2119-27. 2006
    ..g., postoperative morbidity and mortality, recurrence, and survival) in patients with locally advanced esophageal squamous cell carcinoma (ESCC)...
  69. ncbi Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia
    Dario Campana
    Departments of Hematology Oncology and Pathology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Best Pract Res Clin Haematol 15:1-19. 2002
    ..A strong correlation between flow cytometric measurements of MRD during clinical remission and treatment outcome has been demonstrated, suggesting that these assays should be incorporated into treatment protocols...
  70. ncbi Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR
    V H J van der Velden
    Department of Immunology, University Hospital, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands
    Leukemia 16:928-36. 2002
    ..Furthermore, most IGK-Kde rearrangements (90%) can be used for sensitive detection of MRD (< or =10(-4)) by RQ-PCR analysis...
  71. ncbi Association of clinical and pathologic variables with lumpectomy surgical margin status after preoperative diagnosis or excisional biopsy of invasive breast cancer
    Melanie C Smitt
    Department of Radiation Oncology, Stanford University, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
    Ann Surg Oncol 14:1040-4. 2007
    ..To evaluate the impact of preoperative diagnosis in obtaining negative lumpectomy margins...
  72. ncbi Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
    P Gorello
    Institute of Hematology, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy
    Leukemia 20:1103-8. 2006
    ..Thus, reliable, sensitive RQ-PCR assays for NPM1 mutations can now monitor and quantify MRD in AML patients with normal karyotype and NPM1 gene mutations...
  73. ncbi Clinical implications of PRAME gene expression in childhood acute myeloid leukemia
    Daniel Steinbach
    University Children s Hospital, Jena, Germany
    Cancer Genet Cytogenet 133:118-23. 2002
    ..Our results suggest that the expression of PRAME is an indicator of favorable prognosis and could be a useful tool for monitoring minimal residual disease in childhood AML...
  74. ncbi Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia
    Sebastian Scholl
    Department of Internal Medicine II Oncology and Hematology, Friedrich Schiller University, Erlanger Allee 101, 07740 Jena, Germany
    Leuk Res 29:849-53. 2005
    ..One of these patients relapsed with a switch of FAB subtype including loss of Flt3-ITD mutation. Furthermore, in one patient we could identify a Flt3-ITT (internal tandem triplication mutation)...
  75. ncbi Radiofrequency ablation of renal cell carcinoma: part 2, Lessons learned with ablation of 100 tumors
    Debra A Gervais
    Department of Radiology, Massachusetts General Hospital, 55 Fruit St, White 270, Boston, MA 02114, USA
    AJR Am J Roentgenol 185:72-80. 2005
    ..The objective of our study was to review radiofrequency ablation of 100 renal tumors and lessons learned with respect to electrode approach, effects on collecting system, bowel proximity, and patterns of residual disease...
  76. ncbi TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse
    V H J van der Velden
    Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 18:1971-80. 2004
    ....
  77. ncbi Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14
    T Szczepanski
    Department of Immunology, University Hospital Rotterdam Erasmus University Rotterdam, The Netherlands
    Leukemia 15:1415-23. 2001
    ..This immature immunogenotype of precursor-B-ALL with incomplete IGH gene rearrangements was not associated with more aggressive disease...
  78. ncbi Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia
    Lan Lan Smith
    Br J Haematol 133:103-5. 2006
  79. pmc ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Germany
    Breast Cancer Res 10:R76. 2008
    ..Of particular interest is their oestrogen-receptor (ER) status because endocrine adjuvant therapy remains a cornerstone of breast cancer treatment...
  80. ncbi Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer
    Christoph A Klein
    Institut fur Immunologie, Ludwig Maximilians Universitat Munchen, D 80336 MUnchen, Germany
    Lancet 360:683-9. 2002
    ..Disseminated tumour cells can be detected by epithelial markers in mesenchymal tissues and represent targets for adjuvant therapies...
  81. ncbi Micrometastatic disease in breast cancer: clinical implications
    Michail Ignatiadis
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Eur J Cancer 44:2726-36. 2008
    ..This requires the standardisation of micrometastatic cell detection and characterisation, which will allow the incorporation of CTCs/DTCs into prospective clinical trials testing their clinical utility...
  82. ncbi Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Departments of Hematology Oncology, Biostatistics, and Pathology, St Jude Children s Research Hospital, and the University of Tennessee, Memphis TN 38105 2794, USA
    Blood 100:2399-402. 2002
    ..007). These results indicate that peripheral blood may be used to monitor MRD in patients with T-lineage ALL and that peripheral blood MRD may provide strong prognostic information in patients with B-lineage ALL...
  83. pmc Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2
    Christian Flotho
    Department of Pathology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Blood 108:1050-7. 2006
    ..Therefore, this gene is a strong candidate for inclusion in gene expression arrays specifically designed for leukemia diagnosis...
  84. ncbi T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis
    V H J van der Velden
    Department of Immunology, Erasmus MC, Rotterdam, The Netherlands
    Leukemia 16:1372-80. 2002
    ..This method is applicable in the majority of T-ALL patients and in almost half of precursor-B-ALL patients, particularly when used as second-choice target for confirmation of the MRD results obtained via the first-choice target...
  85. ncbi Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Chafika Mazouni
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:2650-5. 2007
    ..To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with histologically defined complete eradication of invasive cancer...
  86. ncbi Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study
    E Stanton Adkins
    J Pediatr Surg 39:931-6. 2004
    ..The authors evaluated the effect of complete primary site resection on event-free survival (EFS), overall survival (OS), and complication rates in patients entered on a high-risk neuroblastoma treatment protocol...
  87. ncbi Surgery for testicular cancer: indication, results and technical aspects
    H Khouni
    Tunis Med 83:78-83. 2005
    ..Laparoscopic approache is a viable staging tool; however, oncologic control of the retroperitoneum has not been reliably determined...
  88. ncbi Effectiveness of superselective and selective neck dissection for advanced nodal metastases after chemoradiation
    K Thomas Robbins
    Division of Otolaryngology Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield 62794 9662, USA
    Arch Otolaryngol Head Neck Surg 131:965-9. 2005
    ..To determine the efficacy of selective and superselective neck dissection for patients with bulky or residual nodal metastasis treated with concomitant intra-arterial cisplatin and radiotherapy...
  89. ncbi Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy
    Robert P Akbari
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Colon Rectum 47:1136-44. 2004
    ..Primary chemoradiation failure for epidermoid carcinoma of the anus is treated by surgical resection. This study evaluates the outcome of salvage surgery at one institution...
  90. ncbi Does clinical and radiological response predict complete tumor control in N2-N3 squamous cell head and neck cancer after non-operative management of the neck?
    Didier Dequanter
    Department of Surgery, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Acta Otolaryngol 126:1225-8. 2006
    ..Consequently, early neck dissection should be advised for patients with complete clinical and radiological response (CCRR) after chemoradiotherapy for tumors with N2-N3 disease...
  91. ncbi The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia
    Claudia Scholl
    Department of Internal Medicine III, University Hospital of Ulm, Robert Koch Str 8, 89081 Ulm, Germany
    Haematologica 90:1626-34. 2005
    ..We evaluated the clinical significance of minimal residual disease (MRD) monitoring in t(9;11)(p22;q23)-positive AML patients using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) analysis...
  92. pmc Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Br J Cancer 91:850-4. 2004
    ..PET negativity at restaging strongly suggests the absence of active disease; histopathological verification is important in patients who show PET positivity...
  93. ncbi Bilateral Wilms' tumors: a single-center experience with 19 cases
    Alastair J W Millar
    Department of Paediatric Surgery, Red Cross Children s Hospital, School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Pediatr Surg 40:1289-94. 2005
    ..The primary aim of management is eradication of neoplasm, while at the same time preserving of renal function...
  94. ncbi Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
    Suzannah Mawdsley
    Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    Int J Radiat Oncol Biol Phys 63:745-52. 2005
    ....
  95. ncbi Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
    Silvia Buonamici
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Blood 99:443-9. 2002
    ..12% might indicate the patient is in a curable state. If confirmed, such thresholds could open the way to a new phase in post-CR therapeutic decision making for patients with inv(16) AML...
  96. ncbi The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer
    Fabio Maria Vecchio
    Department of Pathology, Catholic University of the Sacred Heart, Rome, Italy
    Int J Radiat Oncol Biol Phys 62:752-60. 2005
    ..To examine the relationship between tumor regression grade (TRG) and outcomes in patients with rectal cancer treated with preoperative therapy...
  97. ncbi Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer
    Margherita Gavioli
    III Division of Surgery, Policlinico Hospital, Modena, Italy
    Dis Colon Rectum 48:1851-7. 2005
    ..The complete sterilized and the minimal residual disease often are considered similar. We evaluated the specific incidence of these two conditions and analyzed their impact in terms of local recurrence, distant metastasis, and survival...
  98. ncbi The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment
    Junjun Yang
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China
    Gynecol Oncol 103:479-82. 2006
    ..To analyze retrospectively the prognosis of gestational trophoblastic neoplasia (GTN) patients who achieved normal beta-hCG titer after completing treatment but remained with residual lung tumor...
  99. ncbi [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia]
    Anna Raciborska
    Klinika Chirurgii Onkologicznej Dzieci, Instytu Matki i Dziecka w Warszawie
    Przegl Lek 61:62-6. 2004
    ....
  100. ncbi Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
    A Ghavamzadeh
    Haematology, Oncology and BMT Research Centre, Tehran University of Medical Sciences, Tehran, Iran
    Ann Oncol 17:131-4. 2006
    ..Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear...
  101. ncbi Treatment of diffuse large B-cell lymphoma
    Bertrand Coiffier
    Hematology Department, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, Lyon, France
    Curr Hematol Rep 4:7-14. 2005
    ..Current treatment is based on the combination of chemotherapy including cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) or dose-intense CHOP-like regimen, and rituximab (R-CHOP)...

Research Grants81

  1. DCTD Biopharmaceutical Development
    LARRY ARTHUR; Fiscal Year: 2009
    ..The BDP scientific staff members continued to be active within the extramural community, serving on academic faculties and advisory committees, and presenting scientific findings at national and international meetings. ..
  2. DCTD Biopharmaceutical Development - Type 1 Diabetes RAID projects
    LARRY ARTHUR; Fiscal Year: 2009
    ..The BDP scientific staff members continued to be active within the extramural community, serving on academic faculties and advisory committees, and presenting scientific findings at national and international meetings. ..
  3. DCTD Biopharmaceutical Development
    LARRY ARTHUR; Fiscal Year: 2010
    ..The BDP scientific staff members continued to be active within the extramural community, serving on academic faculties and advisory committees, and presenting scientific findings at national and international meetings. ..
  4. DCTD Biopharmaceutical Development
    David Heimbrook; Fiscal Year: 2011
    ..The BDP scientific staff members continued to be active within the extramural community, serving on academic faculties and advisory committees, and presenting scientific findings at national and international meetings. ..
  5. DCTD Biopharmaceutical Development
    David Heimbrook; Fiscal Year: 2012
    ..The BDP scientific staff members continued to be active within the extramural community, serving on academic faculties and advisory committees, and presenting scientific findings at national and international meetings. ..
  6. T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia
    Laurence J N Cooper; Fiscal Year: 2010
    ..LAY SUMMARY: We will infuse CD19-specific T cells after transplantation to improve survival for patients with acute lymphoblastic leukemia. ..
  7. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2003
    ..Blood, marrow and skin biopsy samples will be obtained for correlative studies relating to immune reconstitution and minimal residual disease and compared with historical controls. ..
  8. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..Blood, marrow and skin biopsy samples will be obtained for correlative studies relating to immune reconstitution and minimal residual disease and compared with historical controls. ..
  9. Clonogenic Characterization of Myeloma Progenitor Cells
    Lia E Perez; Fiscal Year: 2010
    ..Understanding the role of these cell in MM and decipher their survival tools will be essential since eradication of these cells should produce curative results in MM if hypothesis is proven. ..
  10. IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma
    Hing C Wong; Fiscal Year: 2012
    ..Positive outcomes from this proposed study would provide justification for clinical development of this complex as a safe, durable, potent and cell-mediated immunotherapy to treat patients with multiple myeloma. ..
  11. CANCER IMMUNOTHERAPEUTICS PROGRAM
    Andrew Raubitschek; Fiscal Year: 2003
    ..since the last competitive grant review. Of these, 51 are intraprogrammatic publications, 12 are interprogrammatic publications, and 11 are both. ..
  12. DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA
    Jerry Radich; Fiscal Year: 1991
    ..In sum, this proposal could broaden the understanding of the biology of leukemia, aid in its therapy, and provide support to an emerging clinical scientific career...
  13. Identification of Biomarkers for Early Detection of Renal Cell Carcinoma
    Othon Iliopoulos; Fiscal Year: 2010
    ..In addition they may be used as surrogate markers for response to therapy and allow for early changes in biotherapy or targeted molecular therapy in case these latter ones do not work. ..
  14. Identification of Biomarkers for Early Detection of Renal Cell Carcinoma
    Othon Iliopoulos; Fiscal Year: 2009
    ..In addition they may be used as surrogate markers for response to therapy and allow for early changes in biotherapy or targeted molecular therapy in case these latter ones do not work. ..
  15. CANCER AND LEUKEMIA GROUP B--CORRELATIVE SCIENCES
    CLARA BLOOMFIELD; Fiscal Year: 1993
    ..The proposed research should increase our understanding of the biology, diagnosis, classification, and treatment of adults with leukemia, lymphoma, and BrCa...
  16. Active Immunotherapy with Pox Vector Modified DC
    Michael Morse; Fiscal Year: 2004
    ..Therefore, we will subsequently explore the role of IL-2 in augmenting CEA-specific immunity when given with the optimal immunization strategy. ..
  17. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ..abstract_text> ..
  18. TEL/AML1 FUSION IN PEDIATRIC ACUTE LYMPHOCYTIC LEUKEMIA
    D Gilliland; Fiscal Year: 2002
    ..abstract_text> ..
  19. Hematopoietic Cell Transplantation for Malignancies
    Stephen Forman; Fiscal Year: 2006
    ....
  20. Hematopoietic Cell Transplantation for Hematologic Malignancies
    STEPHEN FORMA; Fiscal Year: 2007
    ....
  21. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2007
    ....
  22. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2009
    ....
  23. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2009
    ....
  24. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ..abstract_text> ..
  25. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2009
    ..abstract_text> ..
  26. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ....
  27. TEL/AML1 FUSION IN PEDIATRIC ACUTE LYMPHOCYTIC LEUKEMIA
    D Gilliland; Fiscal Year: 2001
    ..abstract_text> ..
  28. TEL/AML1 FUSION IN PEDIATRIC ACUTE LYMPHOCYTIC LEUKEMIA
    D Gilliland; Fiscal Year: 2000
    ..abstract_text> ..
  29. CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS
    Amy K Wesa; Fiscal Year: 2010
    ..This proposal will adapt modern imaging tools to address this urgent need, while giving insights into ongoing clinical studies of immunotherapy in colorectal cancer. ..
  30. CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS
    ERIC AHRENS; Fiscal Year: 2009
    ..This proposal will adapt modern imaging tools to address this urgent need, while giving insights into ongoing clinical studies of immunotherapy in colorectal cancer. ..
  31. PROTEIN SORTING TO ENDOTHELIAL CELL SECRETORY GRANULES
    Yvonne Datta; Fiscal Year: 2000
    ..The system could theoretically be used therapeutically in a variety of clinical conditions that involve thrombosis and inflammation, such as xenotransplantation and coronary artery disease. ..
  32. PROTEIN SORTING TO ENDOTHELIAL CELL SECRETORY GRANULES
    Yvonne Datta; Fiscal Year: 1999
    ..The system could theoretically be used therapeutically in a variety of clinical conditions that involve thrombosis and inflammation, such as xenotransplantation and coronary artery disease. ..
  33. NOVEL TUMOR ANTIGEN FOR ANTIBODY TARGETING
    Nai Kong Cheung; Fiscal Year: 2001
    ..This information is critical for radioimmunotherapy as well as future antibody-based targeted therapies. ..
  34. PROTEIN SORTING TO ENDOTHELIAL CELL SECRETORY GRANULES
    Yvonne Datta; Fiscal Year: 2001
    ..The system could theoretically be used therapeutically in a variety of clinical conditions that involve thrombosis and inflammation, such as xenotransplantation and coronary artery disease. ..
  35. PROTEIN SORTING TO ENDOTHELIAL CELL SECRETORY GRANULES
    Yvonne Datta; Fiscal Year: 1999
    ..The system could theoretically be used therapeutically in a variety of clinical conditions that involve thrombosis and inflammation, such as xenotransplantation and coronary artery disease. ..
  36. NOVEL TUMOR ANTIGEN FOR ANTIBODY TARGETING
    Nai Kong Cheung; Fiscal Year: 2000
    ..This information is critical for radioimmunotherapy as well as future antibody-based targeted therapies. ..
  37. CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA
    Ariela Noy; Fiscal Year: 2001
    ..In addition, the extensive patient population facilitates the execution of a large number of clinical protocols in a timely manner. ..
  38. CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA
    Ariela Noy; Fiscal Year: 2000
    ..In addition, the extensive patient population facilitates the execution of a large number of clinical protocols in a timely manner. ..
  39. Rare Protein Detection on Cell Surfaces: Ultrasensitive Detection of B-Cell Chron
    William Soo Hoo; Fiscal Year: 2010
    ..The SBIR funds requested in this proposal will accelerate the introduction of an important new technology for the detection of rare cell surface markers for use in both the research and medical communities. ..
  40. CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA
    Ariela Noy; Fiscal Year: 1999
    ..In addition, the extensive patient population facilitates the execution of a large number of clinical protocols in a timely manner. ..
  41. CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA
    Ariela Noy; Fiscal Year: 2002
    ..In addition, the extensive patient population facilitates the execution of a large number of clinical protocols in a timely manner. ..
  42. Maintenance therapy with decitabine for acute myeloid leukemia in first remission
    William Blum; Fiscal Year: 2009
    ..We hope to more accurately predict response to treatment and assess risk of relapse. ..
  43. Maintenance therapy with decitabine for acute myeloid leukemia in first remission
    William G Blum; Fiscal Year: 2010
    ..We hope to more accurately predict response to treatment and assess risk of relapse. ..
  44. NOVEL COMBINATION THERAPY OF NEUROBLASTOMA
    Nai Kong Cheung; Fiscal Year: 2000
    ..Because GD2 is found on a variety of human tumors, these results may have therapeutic implications for other refractory human cancers. ..
  45. NOVEL COMBINATION THERAPY OF NEUROBLASTOMA
    Nai Kong Cheung; Fiscal Year: 1999
    ..Because GD2 is found on a variety of human tumors, these results may have therapeutic implications for other refractory human cancers. ..
  46. TEL/AML1 FUSION IN PEDIATRIC ALL
    D Gilliland; Fiscal Year: 1999
    ....
  47. TEL/AML1 FUSION IN PEDIATRIC ALL
    D Gilliland; Fiscal Year: 2000
    ....
  48. Akt Inhibitors to Treat Ewing's Sarcoma
    Jeffrey Toretsky; Fiscal Year: 2004
    ..Our findings from this Phase I Sun will hopefully lead to a key compound that can be further developed in a Phase II STTR ultimately leading to clinical trials in patients with ESFT. ..
  49. Akt Inhibitors to Treat Ewing's Sarcoma
    Jeffrey Toretsky; Fiscal Year: 2005
    ..Our findings from this Phase I Sun will hopefully lead to a key compound that can be further developed in a Phase II STTR ultimately leading to clinical trials in patients with ESFT. ..
  50. Enhancing the immunogenicity of idiotypes for therapy of Non-Hodgkin's lymphoma
    Yvonne Paterson; Fiscal Year: 2006
    ..We will also have tested 3 possible adjuvants to enhance its delivery. This will set the stage for a Phase II proposal focused on preparations for entering clinical trials. [unreadable] [unreadable] [unreadable]..
  51. IMMUNOGLOBULIN GENE ARRANGEMENT/EXPRESSION IN LEUKEMIA
    GEOFFREY KITCHINGMAN; Fiscal Year: 1991
    ..A positive outcome of these experiments may allow future modifications in therapeutic modalities that are geared toward the actual level of leukemic cells in the body...
  52. Neuroimaging to Assess the Effects of Therapy in Children with Acute Lymphoblasti
    BRUCE T contact SHIRAMIZU; Fiscal Year: 2010
    ..This proposal aims to evaluate CNS structure and chemistry;and cognitive performance, after treatment begins (<6 weeks), and 12 months later in children (3-6 year old) with ALL diagnosed with standard- and intermediate-risk ALL. ..
  53. Neuroimaging to Assess the Effects of Therapy in Children with Acute Lymphoblasti
    Bruce Shiramizu; Fiscal Year: 2009
    ..This proposal aims to evaluate CNS structure and chemistry;and cognitive performance, after treatment begins (<6 weeks), and 12 months later in children (3-6 year old) with ALL diagnosed with standard- and intermediate-risk ALL. ..
  54. Determinants of Relapse Risk After BMT for ALL
    Stephan Grupp; Fiscal Year: 2009
    ..This research will look how a new drug used in bone marrow transplant, called sirolimus, may help prevent relapse in patients and study in the cells how it may act to prevent this problem. ..
  55. Determinants of Relapse Risk After BMT for ALL
    Stephan Grupp; Fiscal Year: 2007
    ..This research will look how a new drug used in bone marrow transplant, called sirolimus, may help prevent relapse in patients and study in the cells how it may act to prevent this problem. ..
  56. Novel Therapies for High-Risk Neuroblastoma
    Julie Park; Fiscal Year: 2004
    ..abstract_text> ..
  57. Novel Therapies for High-Risk Neuroblastoma
    Julie Park; Fiscal Year: 2002
    ..abstract_text> ..
  58. Novel Therapies for High-Risk Neuroblastoma
    Julie Park; Fiscal Year: 2005
    ..abstract_text> ..
  59. Novel Therapies for High-Risk Neuroblastoma
    Julie Park; Fiscal Year: 2003
    ..abstract_text> ..
  60. Novel Therapies for High-Risk Neuroblastoma
    Julie Park; Fiscal Year: 2006
    ..abstract_text> ..
  61. Cell Sorting and Molecular Analysis for Minimal Disease Detection
    Barbara Zehentner; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  62. In Vivo Oncogene-induced Tumorigenesis and Escape
    Lewis A Chodosh; Fiscal Year: 2010
    ..Achieving this goal will permit more effective therapeutic approaches to be developed for the millions of breast cancer survivors at risk for recurrence. ..
  63. Innovative molecular cytogenetic techniques for early leukemia/lymphoma detection
    JOE LUCAS; Fiscal Year: 2005
    ..Early detection of MRD will increase patient survival and profoundly impact cancer patient management. ..
  64. Sensitive, Integrating Multi-Waveguide Biosensor
    Cha Mei Tang; Fiscal Year: 2007
    ..This proposal will develop a sensitive detection for ZAP-70 in B-cells to allow the doctor to identify the patients with aggressive form of CLL and provide treatment immediately. [unreadable] [unreadable] [unreadable]..
  65. Sensitive, Integrating Multi-Waveguide Biosensor
    Cha Mei Tang; Fiscal Year: 2006
    ..This proposal will develop a sensitive detection for ZAP-70 in B-cells to allow the doctor to identify the patients with aggressive form of CLL and provide treatment immediately. [unreadable] [unreadable] [unreadable]..
  66. Molecular and Pharmacologic Correletes of Acute Myeloid Leukemia in Down Syndrome
    JEFFREY TAUB; Fiscal Year: 2007
    ....
  67. DETECTION OF MINIMAL RESIDUAL LEUKEMIA IN CHILDREN
    Dario Campana; Fiscal Year: 1993
    ..Finally, the usefulness of immunologic methods for MRD detection will be estimated in childhood AML, using marrow specimens from patients scheduled to undergo autologous transplantation (specific aim 3)...
  68. Molecular and Pharmacologic Correletes of Acute Myeloid Leukemia in Down Syndrome
    JEFFREY TAUB; Fiscal Year: 2009
    ....
  69. Evaluation of resveratrol and curcumin as therapeutics against high-risk leukemia
    SUSAN ZUNINO; Fiscal Year: 2007
    ..These studies will provide information about whether the plant antioxidants resveratrol and curcumin may be novel and efficient alternatives for the treatment of high-risk leukemia. [unreadable] [unreadable] [unreadable]..
  70. Nanotechnology based magnetic detection for rare cell assays
    MARK DIIORIO; Fiscal Year: 2009
    ....
  71. RADIOIMMUNOTHERAPY OF LYMPHOMA
    Mark Kaminski; Fiscal Year: 2000
    ..These proposed integrated studies should help answer important fundamental questions regarding RIT and help develop this new and promising strategy for the treatment of lymphomas in general. ..
  72. RADIOIMMUNOTHERAPY OF LYMPHOMA
    Mark Kaminski; Fiscal Year: 1999
    ..These proposed integrated studies should help answer important fundamental questions regarding RIT and help develop this new and promising strategy for the treatment of lymphomas in general. ..
  73. CORE--FLOW CYTOMETRY AND CELLULAR IMAGING
    Michael Andreeff; Fiscal Year: 2003
    ..The facility has continuously developed new methodologies in response to the evolving needs of its users. ..
  74. Nanotechnology based magnetic detection for rare cell assays
    MARK DIIORIO; Fiscal Year: 2009
    ....
  75. HEMATOPOIETIC CELL TRANSPLANTATION FOR MALIGNANCY
    Stephen Forman; Fiscal Year: 2000
    ..abstract_text> ..